Recurrent, mutually exclusive point mutations in the TERT promoter were originally discovered in melanoma, and subsequently identified in other tumors, including at a high frequency in primary glioblastoma and oligodendroglioma [56–58]. The gene discussed is TERT; the disease is glioblastoma.